Arrien Pharmaceuticals is a "FIELDS" technology driven biopharmaceutical company focused on discovery and development of innovative and effective drug candidates for the treatment of human cancers. The company currently has three drug candidates for oncology and two other programs in development for non-oncology indications.
ARN-6039 completed its Phase 1 clinical trials and was partnered with Boston Pharmaceuticals in 2017.
ARN-3261 is a SIK2 inhibitor in development, competed its IND enabling studies, and Licensed. Clinical Phase 1a/1b trial will be initiated in Q1 2021.